Insurers’ COVID-19 Notepad: What You Need to Know Now - Week of October 10, 2022
Client Alert | 1 min read | 10.10.22
Courts Dismiss COVID-19 Business Interruption Claims
On September 29, 2022, the district court for the Eastern District of Pennsylvania granted Zurich American Insurance Company’s motion to dismiss an orthopedic healthcare business’ COVID-19 business interruption claim. The court concluded that the policy’s “direct physical loss or damage” provisions do not cover loss of use, which “is not structural or physical damage.” Order at 7. Accordingly, no coverage was available because the plaintiff “has not alleged physical damage to its properties but only economic loss.” Id. The case is Reconstructive Orthopedic Assocs. II, LLC v. Zurich Am. Ins. Co.
On September 29, 2022, the district court for the Western District of Missouri granted Employers Insurance Company of Wausau’s motion to dismiss a restaurant group’s COVID-19 business interruption complaint. The court found the restaurant did not show a direct physical loss or damage that it suffered to trigger coverage under its policy, including its “[g]eneric allegations that the virus was, or likely to be, on surfaces in a property.” Order at 6. According to the court, the virus and the related government shutdown orders do not on their own cause physical loss or damage. Id. at 7. Even if the virus were to have altered the property, which the complaint did not allege, the policy’s contamination exclusion applies to bar coverage. Id. at 9, 15. The case is One Group Hospitality, Inc. v. Employers Insurance Co. of Wausau.
Contacts
Insights
Client Alert | 3 min read | 05.12.25
EU Retaliatory Trade Measures Against the U.S. – Public Consultation
On 8 May 2025, the European Commission published new lists of products potentially subject to EU rebalancing measures in retaliation to U.S. tariffs. The proposed measures would apply if EU-U.S. trade negotiations fail. They are designed to stand alongside previously adopted EU countermeasures, which are currently suspended until 14 July 2025.
Client Alert | 2 min read | 05.09.25
FDA Seeks Stakeholder Consultation on Prescription Drug User Fee Reauthorization
Client Alert | 2 min read | 05.09.25
New SF-328 for Foreign Ownership, Control, and Influence Assessments Approved, Publication Imminent
Client Alert | 10 min read | 05.09.25